All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
14 results for "Cancer" and "Gynecologic Cancers" and "Sarcoma"
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors
This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
A Phase 1 dose escalation study to assess safety and efficacy of ADP-A2M4CD8 as monotherapy or in combination with Nivolumab in HLA-A2+ subjects with MAGE-A4 positive tumors
ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive Tumors
A Multi-Center, Open Label Phase 1/2 Study of Cyt-0851, an Oral Rad51 Inhibitor, in Patients with Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A First-in-Human, Phase 1-2, Dose Escalation Study of BOXR1030 T Cells in Subjects with Advanced GPC3-Positive Solid Tumors
BOXR1030 T Cells in Advanced GPC3-Positive Solid Tumors
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ADP-A2M4 SPEAR T Cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients with Soft Tissue Sarcoma - CEP-2
To estimate the maximum tolerated dose (MTD) of NOX66 in combination with doxorubicin. To characterize the safety and tolerability of NOX66 alone and in combination with doxorubicin.
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors.
The purpose of this study is to learn about the safety and effectiveness of an experimental drug called Mecbotamab Vedotin (BA3011) on a variety of cancers that have tested positive for the AXL protein.
Recognition of Circulating Tumor DNA in Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
A Pivotal Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior Chemotherapy
Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC)
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Ma
Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
A Phase 2, Single-Arm Study of Abemaciclib for Treatment of Advanced Soft Tissue and Bone Sarcoma Identified as having CDK Pathway Alteration
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration